Cargando…

An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy

INTRODUCTION: In a recent clinical trial (ACTG 5257), no difference in viral failure (VF) of a first-line cART containing atazanavir/r (ATV/r) or darunavir/r (DRV/r) was found [1]. For the endpoint of discontinuation due to intolerance, the regimen with DRV/r was superior to that of ATV/r (49% of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cozzi-Lepri, Alessandro, Antinori, Andrea, Bonora, Stefano, Cingolani, Antonella, Cassola, Giovanni, Angarano, Gioacchino, Vullo, Vincenzo, Mussini, Cristina, Gori, Andrea, Maggiolo, Franco, Castagna, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P239
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225250/ https://www.ncbi.nlm.nih.gov/pubmed/25397515 http://dx.doi.org/10.7448/IAS.17.4.19771

Ejemplares similares

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

Variances in Humoral Responses to Different Spike Protein Domains After SARS-CoV-2 Vaccination in Lung and Heart Transplant Recipients
por: Sauer, J., et al.
Publicado: (2022)

Cardiac And Inflammatory Biomarkers And New Or Worsening Heart Failure In High-risk Patients With COVID-19
por: Namdaran, Parhum, et al.
Publicado: (2022)

L’embolie pulmonaire aiguë au cours des infections COVID-19
por: Abdenneji, S., et al.
Publicado: (2022)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

AVALIAÇÃO DO TESTE IMUNOCROMATOGRÁFICO RESIST-3 PARA DETECÇÃO RÁPIDA DE CARBAPENEMASES PERANTE O CENÁRIO PANDÊMICO DA COVID-19
por: de Oliveira, Susan Beatriz Batista, et al.
Publicado: (2022)

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
por: Torti, Carlo, et al.
Publicado: (2011)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
por: Di Biagio, Antonio, et al.
Publicado: (2014)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy
por: Di Biagio, Antonio, et al.
Publicado: (2016)

Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function
por: Postorino, Maria Concetta, et al.
Publicado: (2016)

Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
por: Merlini, Esther, et al.
Publicado: (2021)

Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
por: Merlini, Esther, et al.
Publicado: (2021)

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
por: Rockstroh, J, et al.
Publicado: (2010)

Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc
por: Bernal, Enrique, et al.
Publicado: (2014)

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor
por: Barber, Tristan, et al.
Publicado: (2014)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort
por: d'Arminio Monforte, Antonella, et al.
Publicado: (2017)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era
por: Madeddu, Giordano, et al.
Publicado: (2021)

Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
por: Clumeck, N, et al.
Publicado: (2010)

Factors associated with HPV-DNA clearance in a cohort of HIV-positive patients: role of cART and gender
por: Suardi, Elisa, et al.
Publicado: (2014)

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2016)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice
por: Costarelli, Silvia, et al.
Publicado: (2016)

Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population
por: Cingolani, Antonella, et al.
Publicado: (2017)

High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort
por: Squillace, Nicola, et al.
Publicado: (2016)

The state of PI monotherapy and NRTI-sparing therapy
por: Arribas, JR
Publicado: (2010)

The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI
por: Liu, Shengnan, et al.
Publicado: (2023)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7buph25tgebm5rod5oggaekjnc